Wir sind mit live! Mehr erfahren

Heartbeam

BEAT

Börsenwert 24,6 Mio. $

0,4360 USD

+0,0045

1,04 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

0,4295

-0,0065

1,49 %

1 Tag

1,04 %

5 Tage

-8,61 %

1 Monat

6,5 %

3 Monate

-24,2 %

6 Monate

-46,17 %

Seit Jahresbeginn

-82,06 %

1 Jahr

-74,8 %

5 Jahre

-90,7 %

10 Jahre

-90,7 %

Profil: HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

Mitarbeiter: 16

Gesundheitswesen Gesundheitsinformationsdienste

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 14,3 %

Neutral 85,7 %

Negativ 0 %

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

HeartBeam, Inc. Letter to Shareholders

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.

HeartBeam, Inc. Letter to Shareholders

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam Reports Second Quarter 2026 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.

HeartBeam Reports Second Quarter 2026 Results

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

Zacks Investment Research

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Zacks Investment Research

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.

HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt